分红方面，药明康德A股上市后累计派现140.60亿元。近三年，累计派现104.06亿元。 机构持仓方面，截止2025年9月30日，药明康德十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股2.49亿股，相比上期减少5260.71万股。华夏上证50ETF（510050）位居第七大流通股东， 持股4778.07万股，相比上期减少121.71万股。华泰柏瑞沪深300ETF（510300）位居第八大流通股东， 持股4268.15万股，相比上期减少188.65万股。中欧医疗健康混合A（003095）、易方达沪深300医药ETF （512010）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 资金流向方面，主力资金净流出2.06亿元，特大单买入1.76亿元，占比9.25%，卖出3.35亿元，占比 17.58%；大单买入3.99亿元，占比20.91%，卖出4.46亿元，占比23.38%。 药明 ...

来源：新浪证券-红岸工作室 2月6日，药明康德涨0.74%，成交额34.38亿元，换手率1.42%，总市值2919.01亿元。 异动分析 CRO概念+创新药+人民币贬值受益 1、公司是国际领先的开放式能力与技术平台,为全球生物医药行业提供全方位、一体化的新药研发和生 产服务。 2、国内医药外包行业龙头,是国内最早开始从事医药研发生产外包的CRO和CMO一体化公司,高层管理 团队共拥有超过200项的已授权和申请中的专利成果;其主营业务为小分子化学药的发现、研发及生产的 全方位、一体化平台服务,以全产业链平台的形式面向全球制药企业提供各类新药的研发、生产及配套 服务;公司还在境外提供医疗器械检测及境外精准医疗研发生产服务。 3、根据2024年年报，公司海外营收占比为78.67%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 区间今日近3日近5日近10日近20日主力净流入8223.71万4.43亿1.70亿-2076.06万-14.47亿 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额7.54亿，占总成交额的5.73%。 技术面：筹码平均交易成 ...

2月2日，药明康德跌2.10%，成交额34.25亿元。两融数据显示，当日药明康德获融资买入额2.07亿元， 融资偿还3.14亿元，融资净买入-1.07亿元。截至2月2日，药明康德融资融券余额合计63.64亿元。 分红方面，药明康德A股上市后累计派现140.60亿元。近三年，累计派现104.06亿元。 机构持仓方面，截止2025年9月30日，药明康德十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股2.49亿股，相比上期减少5260.71万股。华夏上证50ETF（510050）位居第七大流通股东， 持股4778.07万股，相比上期减少121.71万股。华泰柏瑞沪深300ETF（510300）位居第八大流通股东， 持股4268.15万股，相比上期减少188.65万股。中欧医疗健康混合A（003095）、易方达沪深300医药ETF （512010）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑： ...

Core Viewpoint - WuXi AppTec's stock price has shown a significant increase, with a year-to-date rise of 10.51% and a market capitalization of approximately 298.83 billion yuan as of January 9 [1][2]. Group 1: Stock Performance - On January 9, WuXi AppTec's stock rose by 2.04%, reaching 100.17 yuan per share, with a trading volume of 2.118 billion yuan and a turnover rate of 0.87% [1]. - The stock has increased by 10.51% year-to-date, with a 10.51% rise over the last five trading days, an 8.00% increase over the last 20 days, and a 0.71% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, WuXi AppTec reported a revenue of 32.857 billion yuan, reflecting a year-on-year growth of 18.61%, and a net profit attributable to shareholders of 12.076 billion yuan, which is an increase of 84.84% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for WuXi AppTec reached 274,100, an increase of 16.39% from the previous period, with an average of 9,024 circulating shares per shareholder [2]. - The company has distributed a total of 14.06 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the last three years [3]. Group 4: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the second-largest circulating shareholder, holding 249 million shares, a decrease of 52.607 million shares from the previous period [3]. - Other notable institutional shareholders include Huaxia SSE 50 ETF and Huatai-PineBridge CSI 300 ETF, both of which have seen a reduction in their holdings [3].

Core Viewpoint - The company, WuXi AppTec, experienced a decline of 2.01% in stock price, with a trading volume of 4.105 billion yuan and a total market capitalization of 261.437 billion yuan [1] Group 1: Company Overview - WuXi AppTec is a leading international open-access capability and technology platform providing comprehensive and integrated new drug research and production services for the global biopharmaceutical industry [2] - The company is a domestic leader in the pharmaceutical outsourcing industry and one of the earliest integrated CRO and CMO companies in China, with a management team holding over 200 authorized and pending patents [2] - The main business involves the discovery, research, and production of small molecule chemical drugs, offering a full-spectrum integrated platform service to global pharmaceutical companies [2][7] Group 2: Financial Performance - For the period from January to September 2025, WuXi AppTec achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61%, and a net profit attributable to shareholders of 12.076 billion yuan, with a year-on-year increase of 84.84% [7] - The company’s revenue from overseas accounts for 78.67%, benefiting from the depreciation of the Renminbi [3] Group 3: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders reached 274,100, an increase of 16.39% from the previous period, with an average of 9,024 circulating shares per person [7] - The company has distributed a total of 14.060 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the past three years [8] - The main shareholders include Hong Kong Central Clearing Limited, which holds 249 million shares, a decrease of 52.6071 million shares from the previous period [8][9]

Core Viewpoint - WuXi AppTec is a leading international open-access capability and technology platform providing comprehensive and integrated new drug research and production services for the global biopharmaceutical industry [2] Group 1: Company Overview - WuXi AppTec is a domestic leader in the pharmaceutical outsourcing industry and one of the earliest companies engaged in integrated CRO (Contract Research Organization) and CMO (Contract Manufacturing Organization) services [2] - The company has a high-level management team with over 200 authorized and pending patent achievements [2] - Its main business involves the discovery, research, and production of small molecule chemical drugs, offering a full-spectrum integrated platform service to global pharmaceutical companies [2][7] Group 2: Financial Performance - For the period from January to September 2025, WuXi AppTec achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61% [7] - The net profit attributable to the parent company was 12.076 billion yuan, with a year-on-year increase of 84.84% [7] - As of September 30, 2025, the company had a total market capitalization of 279.489 billion yuan [1] Group 3: Revenue Composition - The revenue composition of WuXi AppTec includes: - Chemical business: 78.37% - Testing business: 12.93% - Biological business: 6.02% - Other (supplementary): 1.90% - Other business: 0.79% [7] Group 4: Market Dynamics - The company benefits from a 78.67% overseas revenue share, which is positively impacted by the depreciation of the Chinese yuan [3] - The stock experienced a net inflow of 33.2088 million yuan today, with a continuous increase in main funds over the past two days [4][5]

Group 1 - The core viewpoint of the news highlights the significant stock performance and financial growth of WuXi AppTec, with a year-to-date stock price increase of 103.39% and a market capitalization of 322.43 billion yuan [1][2] - WuXi AppTec's main business segments include small molecule chemical drug discovery, research and production services, with revenue contributions of 78.37% from chemical services, 12.93% from testing services, and 6.02% from biological services [1][2] - The company reported a revenue of 20.64% year-on-year growth, reaching 20.799 billion yuan for the first half of 2025, and a net profit increase of 101.92%, amounting to 8.561 billion yuan [2] Group 2 - As of June 30, 2025, the second-largest shareholder of WuXi AppTec is Hong Kong Central Clearing Limited, holding 302 million shares, an increase of 5.602 million shares from the previous period [3] - The seventh-largest shareholder is Huaxia SSE 50 ETF, with 48.998 million shares, an increase of 3.2196 million shares [3] - The eighth-largest shareholder is China Europe Medical Health Mixed A, holding 46.0291 million shares, which decreased by 0.0754 million shares [3]

Core Insights - WuXi AppTec's stock increased by 5.19% to 108.66 CNY per share, with a trading volume of 6.298 billion CNY and a turnover rate of 2.39%, resulting in a total market capitalization of 320.711 billion CNY [1] Company Overview - WuXi AppTec, established on December 1, 2000, and listed on May 8, 2018, is located in Shanghai and Hong Kong. The company provides comprehensive integrated platform services for the discovery, development, and production of small molecule chemical drugs [1] - The revenue composition of WuXi AppTec includes: Chemical business 78.37%, Testing business 12.93%, Biological business 6.02%, Terminated operations 1.90%, Other businesses 0.79% [1] Fund Holdings - According to data, one fund under Guolian An Fund holds a significant position in WuXi AppTec. The Guolian An CSI Pharmaceutical 100A fund (000059) reduced its holdings by 2,800 shares in the second quarter, now holding 35,500 shares, which accounts for 1.04% of the fund's net value, ranking it as the fourth-largest holding [2] - The Guolian An CSI Pharmaceutical 100A fund was established on August 21, 2013, with a latest scale of 178 million CNY. Year-to-date returns are 19.34%, ranking 2403 out of 4222 in its category, while the one-year return is 34.98%, ranking 2704 out of 3779 [2]

Company Overview - WuXi AppTec, established on December 1, 2000, is located in Shanghai and Hong Kong, and was listed on May 8, 2018. The company provides a comprehensive platform for the discovery, development, and manufacturing of small molecule chemical drugs, serving global pharmaceutical companies [1][2]. Financial Performance - For the first half of 2025, WuXi AppTec reported revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, reflecting a significant year-on-year growth of 101.92% [2]. - The company has distributed a total of 13.027 billion yuan in dividends since its A-share listing, with 9.373 billion yuan distributed over the past three years [3]. Stock Performance - As of August 29, WuXi AppTec's stock price increased by 81.74% year-to-date, with a 3.84% rise over the last five trading days, 4.96% over the last 20 days, and 52.52% over the last 60 days [1]. - The stock was trading at 97.61 yuan per share, with a market capitalization of approximately 288.097 billion yuan [1]. Shareholder Structure - As of June 30, 2025, WuXi AppTec had 235,500 shareholders, with the Hong Kong Central Clearing and Settlement System being the second-largest shareholder, holding 302 million shares, an increase of 56.0239 million shares from the previous period [3].

Core Viewpoint - The company, WuXi AppTec, is experiencing a decline in stock price while maintaining a strong position in the CRO and CMO sectors, benefiting from the depreciation of the RMB and showing significant revenue growth in recent reports [1][3][7]. Company Overview - WuXi AppTec is a leading international open-access capability and technology platform providing comprehensive and integrated new drug research and production services for the global biopharmaceutical industry [2]. - The company is a domestic leader in the pharmaceutical outsourcing industry and has been involved in CRO and CMO services since its inception, holding over 200 authorized and pending patents [2]. - The main business focuses on the discovery, research, and production of small molecule chemical drugs, offering a full range of integrated platform services to global pharmaceutical companies [2][7]. Financial Performance - For the first half of 2025, WuXi AppTec achieved revenue of 20.799 billion yuan, representing a year-on-year growth of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, which is a 101.92% increase year-on-year [7]. - The company's overseas revenue accounted for 78.67% of total revenue, benefiting from the depreciation of the RMB [3]. Shareholder Information - As of July 15, the number of shareholders in WuXi AppTec was 235,500, with no change in the average circulating shares per person [7]. - The company has distributed a total of 13.027 billion yuan in dividends since its A-share listing, with 9.373 billion yuan distributed over the past three years [8]. Market Activity - On August 27, WuXi AppTec's stock price fell by 1.45%, with a trading volume of 6.037 billion yuan and a turnover rate of 2.50%, resulting in a total market capitalization of 282.705 billion yuan [1]. - The stock has seen a net outflow of 441 million yuan from major funds today, with a continuous reduction in holdings over the past two days [4][5].